Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 274

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Whole-genome sequencing of 508 patients identifies key molecular features associated with poor prognosis in esophageal squamous cell carcinoma

Open access
Cui, Yongping, Chen, Hongyan, Xi, Ruibin, Cui, Heyang, Zhao, Yahui, Xu, Enwei, Yan, Ting, Lu, Xiaomei, Huang, Furong, Kong, Pengzhou, Li, Yang, Zhu, Xiaolin, Wang, Jiawei, Zhu, Wenjie, Wang, Jie, Ma, Yanchun, Zhou, Yong, Guo, Shiping, Zhang, Ling, Liu, Yiqian, Wang, Bin, Xi, Yanfeng, Sun, Ruifang, Yu, Xiao, Zhai, Yuanfang, Wang, Fang, Yang, Jian, Yang, Bin, Cheng, Caixia, Liu, Jing, Song, Bin, Li, Hongyi, Wang, Yi, Zhang, Yingchun, Cheng, Xiaolong, Zhan, Qimin, Li, Yanhong, Liu, Zhihua·2020·Cell Research

Abstract

Esophageal squamous cell carcinoma (ESCC) is a poor-prognosis cancer type with limited understanding of its molecular etiology. Using 508 ESCC genomes, we identified five novel significantly mutated genes and uncovered mutational signature clusters associated with metastasis and patients’ outcomes. Several functional assays implicated that NFE2L2 may act as a tumor suppressor in ESCC and that mutations in NFE2L2 probably impaired its tumor-suppressive function, or even conferred oncogenic activities. Additionally, we found that the NFE2L2 mutations were significantly associated with worse prognosis of ESCC. We also identified potential noncoding driver mutations including hotspot mutations in the promoter region of SLC35E2 that were correlated with worse survival. Approximately 5.9% and 15.2% of patients had high tumor mutation burden or actionable mutations, respectively, and may benefit from immunotherapy or targeted therapies. We found clinically relevant coding and noncoding genomic alterations and revealed three major subtypes that robustly predicted patients’ outcomes. Collectively, we report the largest dataset of genomic profiling of ESCC useful for developing ESCC-specific biomarkers for diagnosis and treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41422-020-0333-6

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

See all 274

Metadata

Authors
Cui, Y., Chen, H., Xi, R., Cui, H., Zhao, Y., Xu, E., Yan, T., Lu, X., Huang, F., Kong, P., Li, Y., Zhu, X., Wang, J., Zhu, W., Wang, J., Ma, Y., Zhou, Y., Guo, S., Zhang, L., Liu, Y., Wang, B., Xi, Y., Sun, R., Yu, X., Zhai, Y., Wang, F., Yang, J., Yang, B., Cheng, C., Liu, J., Song, B., Li, H., Wang, Y., Zhang, Y., Cheng, X., Zhan, Q., Li, Y., & Liu, Z.
Venue
Cell Research
Published
2020-05-12
Volume
30
Issue
10
Pages
902-913
ISSN
  • 1001-0602 (ISSN-L)
  • 1748-7838
OpenAlex
W3024000868
Cited by
274
References
54
FWCI
31.63
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Whole-genome sequencing of 508 patients identifies key molecular features associated with poor prognosis in esophageal squamous cell carcinoma. https://app.cochat.ai/papers/10.1038/s41422-020-0333-6
The paper
Cui, Y., Chen, H., Xi, R., Cui, H., Zhao, Y., Xu, E., Yan, T., Lu, X., Huang, F., Kong, P., Li, Y., Zhu, X., Wang, J., Zhu, W., Wang, J., Ma, Y., Zhou, Y., Guo, S., Zhang, L., . . . Liu, Z. (2020). Whole-genome sequencing of 508 patients identifies key molecular features associated with poor prognosis in esophageal squamous cell carcinoma. Cell Research. https://doi.org/10.1038/s41422-020-0333-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.